We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
Symbicort is presently marketed for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
Results from the safety study showed that Symbicort demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Pulmicort alone.
Symbicort pressurized metered dose inhaler (pMDI) is a combination of two active therapies – formoterol, a long-acting beta-adrenoceptor agonist (LABA) and budesonide, an inhaled corticosteroid (ICS). The study was conducted as part of FDA’s post marketing requirement. Note that the FDA had instructed all U.S. manufacturers of LABA-containing asthma products, like Symbicort, to conduct studies to determine the safety of a combination of LABAs with an ICS.
The study data establishes the safety of AstraZeneca's ICS/LABA combination therapy.
The study, which began in 2011, has been conducted in 25 countries in asthma patients aged 12 years or above. AstraZeneca is currently discussing the results with the FDA for the agency’s post-marketing requirements.
Symbicort is one of the leading products in AstraZeneca’s respiratory portfolio. Due to persistent generic threat for the product, the company has been focused on a label expansion for Symbicort to boost its sales.
Symbicort is being studied for mild asthma in two phase III studies, with results from both the studies expected next year. AstraZeneca is also developing Symbicort as a breath-actuated inhaler for both asthma and COPD patients. Regulatory filing in the U.S. is slated for 2018.
Astrazeneca currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical drugs sector include BioSpecifics Technologies Corp. , Evotec AG and Ohr Pharmaceutical, Inc. . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
AstraZeneca PLC (AZN - Free Report) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
Symbicort is presently marketed for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
Results from the safety study showed that Symbicort demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Pulmicort alone.
Symbicort pressurized metered dose inhaler (pMDI) is a combination of two active therapies – formoterol, a long-acting beta-adrenoceptor agonist (LABA) and budesonide, an inhaled corticosteroid (ICS). The study was conducted as part of FDA’s post marketing requirement. Note that the FDA had instructed all U.S. manufacturers of LABA-containing asthma products, like Symbicort, to conduct studies to determine the safety of a combination of LABAs with an ICS.
The study data establishes the safety of AstraZeneca's ICS/LABA combination therapy.
The study, which began in 2011, has been conducted in 25 countries in asthma patients aged 12 years or above. AstraZeneca is currently discussing the results with the FDA for the agency’s post-marketing requirements.
Symbicort is one of the leading products in AstraZeneca’s respiratory portfolio. Due to persistent generic threat for the product, the company has been focused on a label expansion for Symbicort to boost its sales.
Symbicort is being studied for mild asthma in two phase III studies, with results from both the studies expected next year. AstraZeneca is also developing Symbicort as a breath-actuated inhaler for both asthma and COPD patients. Regulatory filing in the U.S. is slated for 2018.
ASTRAZENECA PLC Price
ASTRAZENECA PLC Price | ASTRAZENECA PLC Quote
Zacks Rank & Key Picks
Astrazeneca currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical drugs sector include BioSpecifics Technologies Corp. , Evotec AG and Ohr Pharmaceutical, Inc. . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>